In addition, the patients with a high level of GPX2 expression in their TUR specimen showed significantly better progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS) than those with low level of GPX2 expression (Figure 3L-3N). This evidence concerns the gene GPX2 and cancer.